Related Experiment Video
Updated: Aug 24, 2026
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
Adenoviral interleukin-3 gene-radiation therapy for prostate cancer in mouse model
Young-Taek Oh1, Daniel W C Chen, Graeme J Dougherty
1Department of Radiation Oncology, Ajou University School of Medicine, Paldal Gu, Suwon, South Korea. ohyoung@ajou.ac.kr
Purpose:
The radiosensitizing effect of IL-3 gene therapy was evaluated on the syngeneic mouse prostate cancer model.
Methods And Materials:
An adenoviral vector was used to deliver the mIL-3 alpha gene into syngeneic murine prostate (TRAMP-C1) cancer cells growing in a subcutaneous site and the tumor response to irradiation was assessed.
Results:
Ad-mIL-3 gene therapy showed no tumor growth delay without radiation. However, intratumoral Ad-mIL-3 injection with radiation therapy showed marked tumor growth delay that was significantly greater than that of radiation alone.
Conclusions:
The combined intratumoral Ad-mIL-3 gene therapy and radiation therapy is a valuable option for further clinical evaluation.
Insights
Interleukin-3 (IL-3) gene therapy enhances radiation effectiveness in a mouse prostate cancer model. Combining IL-3 gene therapy with radiation significantly improved tumor growth delay compared to radiation alone.
Area of Science:
- Oncology
- Gene Therapy
- Radiation Oncology
Background:
- Prostate cancer remains a significant health concern.
- Developing novel therapeutic strategies to improve treatment outcomes is crucial.
- Gene therapy offers a promising avenue for targeted cancer treatment.
Purpose of the Study:
- To evaluate the radiosensitizing effect of Interleukin-3 (IL-3) gene therapy.
- To assess the efficacy of IL-3 gene therapy in combination with radiation.
- To investigate the potential of this combined approach in a syngeneic mouse prostate cancer model.
Main Methods:
- Utilized an adenoviral vector for delivering the murine IL-3 alpha gene (Ad-mIL-3).
- Administered gene therapy to syngeneic murine prostate (TRAMP-C1) cancer cells in vivo.
- Assessed tumor response to irradiation following gene therapy.
Main Results:
- Ad-mIL-3 gene therapy alone did not significantly delay tumor growth.
- Intratumoral Ad-mIL-3 injection combined with radiation therapy resulted in marked tumor growth delay.
- The combination therapy demonstrated significantly greater tumor growth delay than radiation alone.
Conclusions:
- Combined intratumoral Ad-mIL-3 gene therapy and radiation therapy show significant potential.
- This combination represents a valuable option for further clinical investigation.
- Further studies are warranted to explore the clinical applicability of this approach.
